Trials / Completed
CompletedNCT00452686
Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix (dTpa) Vaccine and the Chinese DT Vaccine, When Administered as Booster Vaccination in Healthy Children Aged 6-8 Years
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 660 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Years – 8 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and immunogenicity of a booster dose of GSK Biologicals' reduced antigen content diphtheria, tetanus, acellular pertussis (dTpa) vaccine - Boostrix in comparison with Chinese DT vaccine, in children 6-8 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Boostrix | |
| BIOLOGICAL | Chinese DT vaccine |
Timeline
- Start date
- 2007-03-01
- Completion
- 2007-05-01
- First posted
- 2007-03-27
- Last updated
- 2016-10-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00452686. Inclusion in this directory is not an endorsement.